

(DANRE) adra2a Blocking Peptide (Center)
Synthetic peptide
Catalog # BP21215c

Specification

(DANRE) adra2a Blocking Peptide (Center) - Product Information

Primary Accession [Q90WY4](#)

(DANRE) adra2a Blocking Peptide (Center) - Additional Information

Other Names

Alpha-2A adrenergic receptor, Alpha-2A adrenoreceptor, Alpha-2A adrenoceptor, Alpha-2AAR, adra2a

Target/Specificity

The synthetic peptide sequence is selected from aa 223-236 of HUMAN adra2a

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

(DANRE) adra2a Blocking Peptide (Center) - Protein Information

Name adra2a {ECO:0000250|UniProtKB:P08913}

Function

Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The order of potency for this receptor is dexmedetomidine > oxymetazoline = epinephrine > norepinephrine.

Cellular Location

Cell membrane; Multi-pass membrane protein.

(DANRE) adra2a Blocking Peptide (Center) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

(DANRE) adra2a Blocking Peptide (Center) - Images

(DANRE) adra2a Blocking Peptide (Center) - Background

Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The order of potency for this receptor is dexmedetomidine > oxymetazoline = epinephrine > norepinephrine.

(DANRE) adra2a Blocking Peptide (Center) - References

Ruuskanen J.O.,et al.Mol. Biol. Evol. 21:14-28(2004).
Ruuskanen J.O.,et al.Br. J. Pharmacol. 144:165-177(2005).